Why the study?
Elevated blood pressure incurs a major health and economic burden in low-income and middle-income countries, prompting an assessment of the cost-effectiveness of a fixed-combination, low-dose, triple-pill strategy evaluated in Sri Lanka.
Does fixed-combination, low-dose, triple-pill antihypertensive therapy improve cost-effectiveness compared to usual care in patients with mild-to-moderate hypertension?
Population
Patients with mild-to-moderate hypertension in Sri Lanka
Comparison
Triple-pill antihypertensive therapy (amlodipine, telmisartan, chlorthalidone) vs usual care
Design
Within-trial (6-month) and modelled (10-year) economic evaluation
Follow-up
6 months (within-trial) and 10 years (modelled)
Authors
Loading...
Triple-pill strategy may be cost-effective in Sri Lanka; leaves open broader LMIC adoption pending prospective data.
Does fixed-combination, low-dose, triple-pill antihypertensive therapy improve cost-effectiveness compared to usual care in patients with mild-to-moderate hypertension?
A fixed-combination, low-dose, triple-pill antihypertensive strategy is cost-effective compared to usual care for patients with mild-to-moderate hypertension in Sri Lanka.
Lung et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: